Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya

Jillian Pintye, Agnes Langat, Benson Singa, John Kinuthia, Beryne Odeny, Abraham Katana, Lucy Nganga, Grace John-Stewart, Christine J. McGrath

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure prophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed uninfected (HEU) infants. Materials and Methods. We included PCR-confirmed HEU infants enrolled in a cross-sectional survey of mother-infant pairs conducted between July and December 2013 in Kenya. Maternal ART regimen during pregnancy was determined by self-report and clinic records. Six-week and 9-month z-scores for weight-for-age (WAZ), weight-for-length (WLZ), length-for-age (LAZ), and head circumference-for-age (HCAZ) were compared among HEU infants with and without TDF exposure using t-tests and multivariate linear regression models. Results. Among 277 mothers who received ART during pregnancy, 63% initiated ART before pregnancy, of which 89 (32%) used TDF. No differences in birth weight (3.0 kg versus 3.1 kg, p = 0.21) or gestational age (38 weeks versus 38 weeks, p = 0.16) were detected between TDF-exposed and TDF-unexposed infants. At 6 weeks, unadjusted mean WAZ was lower among TDF-exposed infants (-0.8 versus -0.4, p = 0.03), with a trend towards association in adjusted analyses (p = 0.06). There were no associations between prenatal TDF use and WLZ, LAZ, and HCAZ in 6-week or 9-month infant cohorts. Conclusion. Maternal TDF use did not adversely affect infant growth compared to other regimens.

    Original languageEnglish (US)
    Article number276851
    JournalInfectious Diseases in Obstetrics and Gynecology
    Volume2015
    DOIs
    StatePublished - 2015

    Fingerprint

    Tenofovir
    Kenya
    Pregnancy Outcome
    Mothers
    HIV
    Growth
    Pregnancy
    Linear Models
    Weights and Measures

    ASJC Scopus subject areas

    • Obstetrics and Gynecology
    • Infectious Diseases
    • Dermatology

    Cite this

    Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya. / Pintye, Jillian; Langat, Agnes; Singa, Benson; Kinuthia, John; Odeny, Beryne; Katana, Abraham; Nganga, Lucy; John-Stewart, Grace; McGrath, Christine J.

    In: Infectious Diseases in Obstetrics and Gynecology, Vol. 2015, 276851, 2015.

    Research output: Contribution to journalArticle

    Pintye, J, Langat, A, Singa, B, Kinuthia, J, Odeny, B, Katana, A, Nganga, L, John-Stewart, G & McGrath, CJ 2015, 'Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya', Infectious Diseases in Obstetrics and Gynecology, vol. 2015, 276851. https://doi.org/10.1155/2015/276851
    Pintye, Jillian ; Langat, Agnes ; Singa, Benson ; Kinuthia, John ; Odeny, Beryne ; Katana, Abraham ; Nganga, Lucy ; John-Stewart, Grace ; McGrath, Christine J. / Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya. In: Infectious Diseases in Obstetrics and Gynecology. 2015 ; Vol. 2015.
    @article{a9a4ed78745f4c688a22057edb4c625c,
    title = "Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya",
    abstract = "Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure prophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed uninfected (HEU) infants. Materials and Methods. We included PCR-confirmed HEU infants enrolled in a cross-sectional survey of mother-infant pairs conducted between July and December 2013 in Kenya. Maternal ART regimen during pregnancy was determined by self-report and clinic records. Six-week and 9-month z-scores for weight-for-age (WAZ), weight-for-length (WLZ), length-for-age (LAZ), and head circumference-for-age (HCAZ) were compared among HEU infants with and without TDF exposure using t-tests and multivariate linear regression models. Results. Among 277 mothers who received ART during pregnancy, 63{\%} initiated ART before pregnancy, of which 89 (32{\%}) used TDF. No differences in birth weight (3.0 kg versus 3.1 kg, p = 0.21) or gestational age (38 weeks versus 38 weeks, p = 0.16) were detected between TDF-exposed and TDF-unexposed infants. At 6 weeks, unadjusted mean WAZ was lower among TDF-exposed infants (-0.8 versus -0.4, p = 0.03), with a trend towards association in adjusted analyses (p = 0.06). There were no associations between prenatal TDF use and WLZ, LAZ, and HCAZ in 6-week or 9-month infant cohorts. Conclusion. Maternal TDF use did not adversely affect infant growth compared to other regimens.",
    author = "Jillian Pintye and Agnes Langat and Benson Singa and John Kinuthia and Beryne Odeny and Abraham Katana and Lucy Nganga and Grace John-Stewart and McGrath, {Christine J.}",
    year = "2015",
    doi = "10.1155/2015/276851",
    language = "English (US)",
    volume = "2015",
    journal = "Infectious Diseases in Obstetrics and Gynecology",
    issn = "1064-7449",
    publisher = "Hindawi Publishing Corporation",

    }

    TY - JOUR

    T1 - Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya

    AU - Pintye, Jillian

    AU - Langat, Agnes

    AU - Singa, Benson

    AU - Kinuthia, John

    AU - Odeny, Beryne

    AU - Katana, Abraham

    AU - Nganga, Lucy

    AU - John-Stewart, Grace

    AU - McGrath, Christine J.

    PY - 2015

    Y1 - 2015

    N2 - Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure prophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed uninfected (HEU) infants. Materials and Methods. We included PCR-confirmed HEU infants enrolled in a cross-sectional survey of mother-infant pairs conducted between July and December 2013 in Kenya. Maternal ART regimen during pregnancy was determined by self-report and clinic records. Six-week and 9-month z-scores for weight-for-age (WAZ), weight-for-length (WLZ), length-for-age (LAZ), and head circumference-for-age (HCAZ) were compared among HEU infants with and without TDF exposure using t-tests and multivariate linear regression models. Results. Among 277 mothers who received ART during pregnancy, 63% initiated ART before pregnancy, of which 89 (32%) used TDF. No differences in birth weight (3.0 kg versus 3.1 kg, p = 0.21) or gestational age (38 weeks versus 38 weeks, p = 0.16) were detected between TDF-exposed and TDF-unexposed infants. At 6 weeks, unadjusted mean WAZ was lower among TDF-exposed infants (-0.8 versus -0.4, p = 0.03), with a trend towards association in adjusted analyses (p = 0.06). There were no associations between prenatal TDF use and WLZ, LAZ, and HCAZ in 6-week or 9-month infant cohorts. Conclusion. Maternal TDF use did not adversely affect infant growth compared to other regimens.

    AB - Background. Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatment (ART) and preexposure prophylaxis regimens. We evaluated the relationship of prenatal TDF use and growth outcomes among Kenyan HIV-exposed uninfected (HEU) infants. Materials and Methods. We included PCR-confirmed HEU infants enrolled in a cross-sectional survey of mother-infant pairs conducted between July and December 2013 in Kenya. Maternal ART regimen during pregnancy was determined by self-report and clinic records. Six-week and 9-month z-scores for weight-for-age (WAZ), weight-for-length (WLZ), length-for-age (LAZ), and head circumference-for-age (HCAZ) were compared among HEU infants with and without TDF exposure using t-tests and multivariate linear regression models. Results. Among 277 mothers who received ART during pregnancy, 63% initiated ART before pregnancy, of which 89 (32%) used TDF. No differences in birth weight (3.0 kg versus 3.1 kg, p = 0.21) or gestational age (38 weeks versus 38 weeks, p = 0.16) were detected between TDF-exposed and TDF-unexposed infants. At 6 weeks, unadjusted mean WAZ was lower among TDF-exposed infants (-0.8 versus -0.4, p = 0.03), with a trend towards association in adjusted analyses (p = 0.06). There were no associations between prenatal TDF use and WLZ, LAZ, and HCAZ in 6-week or 9-month infant cohorts. Conclusion. Maternal TDF use did not adversely affect infant growth compared to other regimens.

    UR - http://www.scopus.com/inward/record.url?scp=84956880436&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84956880436&partnerID=8YFLogxK

    U2 - 10.1155/2015/276851

    DO - 10.1155/2015/276851

    M3 - Article

    VL - 2015

    JO - Infectious Diseases in Obstetrics and Gynecology

    JF - Infectious Diseases in Obstetrics and Gynecology

    SN - 1064-7449

    M1 - 276851

    ER -